DMD and Hypomagnesemia: A Phase 2 trial of SRP-5051, a conjugate of a proprietary peptide with Eteplirsen, a PMO designed to skip exon 51 from the DMD gene to re-frame the dystrophin mRNA in amenable patients, showed substantially better efficacy, including higher increases in dystrophin protein and exon skipping with clinically manageable hypomagnesemia, as reported by Sarepta Therapeutics (Sorrentino, 2024).